Atherotech, Inc., is a privately held medical diagnostic company and specialty reference laboratory that has developed and is marketing the Vertical Auto Profile (VAP™) Test, a next-generation cholesterol test that improves the detection rate of those at risk for heart disease. The company provides its unique testing services to Physicians, Hospitals, Clinics, and other Laboratories throughout the United States. Atherotech is a "CLIA" approved clinical reference laboratory located in Birmingham, Alabama.
The VAP Test replaces the routine Lipid Panel and is becoming the new standard of care for cholesterol risk assessment.
The VAP Test was developed by company founder Jere Segrest, M.D., a recognized expert in the study of cholesterol. Segrest, who now serves as a consultant to Atherotech, is an internal medicine physician, acting professor, and director of the Atherosclerosis Research Unit at the University of Alabama, Birmingham.
The VAP Test is an expanded cholesterol profile that provides direct, detailed measurements of cholesterol, or lipid, subclasses that play important roles in the development of cardiovascular disease, the No. 1 cause of death in the United States. The test identifies up to 90 percent of people at risk for heart disease-nearly twice the detection rate of the traditional cholesterol tests developed in the 1970s. Measurements obtained using the VAP Test also provide doctors with a foundation to develop individualized treatment plans while continuing to track patients' progress in battling heart disease.
The price of the VAP Test is comparable to the traditional cholesterol test and is reimbursed by Medicare and most insurance carriers. Also,
Atherotech participates in and has its accuracy confirmed by three highly recognized Lipid Standardization Programs-the American Association of Bioanalysts, the New York State Department of Health, and the Northwest Lipid Research Laboratories.